OxyContin, the controlled-release form of oxycodone, is typically detectable in urine for roughly two to three days after a single dose, in blood and saliva for about one to two days, and in hair for up to 90 days. These windows shift considerably depending on the test used, how much you took, and how your body processes the drug. The controlled-release formulation also behaves differently from immediate-release oxycodone, extending detection times in ways that catch some people off guard.
Urine Detection
Urine testing is by far the most common method used to screen for oxycodone, whether in pain management clinics, workplace drug panels, or legal monitoring programs. In a study comparing immediate-release and controlled-release oxycodone, immunoassay screening detected the drug for an average of about 41 hours after an immediate-release dose and about 51 hours after a controlled-release dose. When researchers used more sensitive techniques to look at specific metabolites, the longest-lasting marker stayed detectable for about 48 hours with the immediate-release version and about 65 hours with the controlled-release formulation.1Journal of Analytical Toxicology. Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites Using LC–MS-MS
The parent drug, oxycodone itself, cleared urine fastest. In people with normal metabolic activity who took the immediate-release form, oxycodone was gone from urine within about 24 hours. But the controlled-release form kept oxycodone detectable for up to 48 hours in the same metabolic group. People who are genetically slower at breaking down oxycodone also showed detection out to 48 hours regardless of formulation.1Journal of Analytical Toxicology. Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites Using LC–MS-MS
A practical note: standard urine immunoassay panels for opioids often do not reliably detect oxycodone at all. Many workplace drug screens use a broad opiate immunoassay designed around morphine and codeine, which can miss oxycodone entirely. Dedicated oxycodone-specific immunoassays exist and perform well at a 100 ng/mL cutoff, catching all positive specimens at or above that level in validation testing.2PubMed Central. Comparison of Response of DRI Oxycodone Semiquantitative Immunoassay With True Oxycodone Values Determined by Liquid Chromatography Combined With Tandem Mass Spectrometry But cross-reactivity across different immunoassay platforms is inconsistent, and manufacturers do not always provide thorough data on which drugs might cause false positives or negatives.3PubMed Central. A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing If you are being monitored for compliance with a prescription, a negative screen does not necessarily mean you are not taking the drug; it may mean the wrong assay was used.
Blood and Oral Fluid Detection
Blood and saliva tests have shorter detection windows than urine but are useful in different contexts, particularly roadside testing or acute clinical situations. In a controlled study where 12 healthy adults received a single 20 mg controlled-release dose, oxycodone and its metabolites appeared in oral fluid within 15 to 30 minutes and in blood within 30 minutes to two hours. At a 1 ng/mL cutoff, the average detection time in oral fluid was about 34 hours for both oxycodone and its primary metabolite noroxycodone.4Journal of Analytical Toxicology. Prescription Opioids. III. Disposition of Oxycodone in Oral Fluid and Blood Following Controlled Single-Dose Administration
Oral fluid concentrations of oxycodone ran roughly five times higher than blood concentrations at the same time points, which means saliva tests tend to stay positive longer than blood draws at comparable cutoffs. Detection in oral fluid exceeded blood by about twofold when using the same threshold. The broader literature on oral fluid testing reports that prescription opioids are generally detectable in saliva for anywhere from a few hours up to about 72 hours, depending on dose, how the drug was taken, and the cutoff the lab applies.5The Journal of Applied Laboratory Medicine. Oral Fluid Drug Testing in Pain Management Practice: Factors to Consider Before Choosing the Alternative Biological Matrix
Blood testing for oxycodone is mainly used in hospital emergency settings, forensic investigations, or driving-under-the-influence cases. Because blood concentrations fall off faster than either saliva or urine, a negative blood test does not rule out recent use if more than a day has passed.
Hair Testing
Hair analysis can detect oxycodone for up to 90 days after use, and sometimes longer depending on how much hair is available and how the sample is segmented. Unlike urine or blood, hair does not measure what is circulating in your body right now. Instead, drug molecules get incorporated into the hair shaft as it grows, creating a timeline that can be read backward. Researchers have validated screening methods capable of detecting over 150 substances, including oxycodone, in single hair strands at extremely low concentrations. Even single-dose cases produced characteristic concentration peaks in hair collected one to two months after ingestion.6Wiley Online Library / PubMed Central. Single hair analysis: Validation of a screening method for over 150 analytes and application on documented single-dose cases
Hair testing has important limitations. It takes roughly one to two weeks after drug exposure for the affected hair to grow past the scalp and become collectible, so very recent use does not show up. Hair color and cosmetic treatments can also affect results. These tests are mainly used in forensic and legal contexts rather than clinical pain management.
Sweat Patch Testing
Sweat patches are adhesive collection devices worn on the skin for days or even a full week. They accumulate drug residues excreted through the skin over that entire period, providing a cumulative picture of exposure rather than a snapshot. Research on opioid users has shown that sweat testing offers a relatively noninvasive way to monitor drug use over extended periods, making it useful for probation monitoring and substance abuse treatment programs.7Journal of Analytical Toxicology. Sweat Testing in Opioid Users with a Sweat Patch Because the patch stays on continuously, it can catch intermittent use that a single urine test might miss if the timing is unlucky.
Why the Controlled-Release Formulation Takes Longer to Clear
OxyContin is specifically designed to release oxycodone slowly over about 12 hours, compared with immediate-release tablets that dump the full dose into your bloodstream within an hour or two. This slow-drip design means the drug is still being absorbed hours after you swallow it, so the clock on elimination effectively starts later. The roughly 10-hour difference in immunoassay detection times between the two formulations reflects this delayed absorption profile.1Journal of Analytical Toxicology. Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites Using LC–MS-MS
Reformulated OxyContin tablets, which were redesigned to resist crushing and snorting, add another layer. When the abuse-deterrent version is crushed and administered intranasally, it produces lower peak blood concentrations and takes longer to reach those peaks compared with the older crushable tablets. Finely crushed abuse-deterrent tablets reached peak concentration at about 2 hours versus 1 hour for the original formulation, and coarsely crushed versions took about 3 hours.8PubMed Central. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin tablets compared with original OxyContin tablets in healthy adults Total exposure over time remained similar, but the flattened, delayed peak is part of what makes the reformulated version less appealing to misuse and could slightly extend the tail end of detection.
How Your Liver and Kidneys Change the Timeline
Oxycodone is primarily broken down by liver enzymes, with only a small fraction leaving the body unchanged through the kidneys.9European Journal of Pharmaceutical Sciences. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation That means anything impairing liver or kidney function can substantially extend how long the drug sticks around.
The liver effect is dramatic. In patients with cirrhosis awaiting a liver transplant, the elimination half-life of oxycodone averaged about 14 hours, with some patients taking over 24 hours. After transplantation, the same patients cleared the drug with an average half-life of about 3.4 hours. That is a roughly fourfold difference, meaning a person with severe liver disease might test positive for considerably longer than someone with a healthy liver.10PubMed. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation More broadly, moderate to severe liver impairment reduces the clearance of oxycodone and increases the amount that actually reaches the bloodstream after an oral dose.11PubMed. Analgesics in patients with hepatic impairment: pharmacology and clinical implications
Kidney disease has a parallel effect. Oxycodone and its active metabolites are cleared through the kidneys, and in people with end-stage renal failure, the elimination half-life is prolonged because of both increased distribution into tissues and reduced clearance. Metabolite concentrations, particularly noroxycodone, build up higher in these patients.12Journal of Clinical Anesthesia. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation Clinical guidelines recommend starting oxycodone at lower doses in older adults with chronic kidney disease and monitoring closely, because the drug lingers longer and its effects accumulate.13PubMed Central. Opioid Management in Older Adults with Chronic Kidney Disease: A Review
Genetic Differences in Drug Metabolism
Your genetic makeup influences how quickly you process oxycodone, and the differences are not small. Two liver enzymes do most of the work: CYP3A4 handles the bulk of oxycodone metabolism, while CYP2D6 converts a portion into oxymorphone, a metabolite with roughly 40 to 60 times the painkilling potency of oxycodone itself.9European Journal of Pharmaceutical Sciences. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation
People inherit different versions of the CYP2D6 gene, creating a spectrum from poor metabolizers (who break oxycodone down slowly) to ultra-rapid metabolizers (who process it fast). In a study of surgical patients, the ratio of oxymorphone to oxycodone nearly tripled from poor metabolizers to ultra-rapid metabolizers, confirming that genetics drive big differences in how the drug is broken down. Poor metabolizers also consumed more oxycodone to achieve the same pain relief.14PLOS ONE. CYP2D6 Genotype Dependent Oxycodone Metabolism in Postoperative Patients From a detection standpoint, poor metabolizers end up with higher blood concentrations of both oxycodone and noroxycodone, which would extend detection windows.15Forensic Science International: Genetics. Oxycodone findings and CYP2D6 function in postmortem cases
You will not typically know your CYP2D6 status unless you have had pharmacogenomic testing. Roughly 5 to 10 percent of people of European descent are poor metabolizers, and a smaller percentage are ultra-rapid metabolizers. If you have ever noticed that oxycodone seems to hit you harder or last longer than expected, genetic variation in this enzyme is one plausible explanation.
Drug Interactions That Slow Clearance
Because oxycodone depends on CYP3A4 and CYP2D6 for metabolism, other medications that inhibit those enzymes can meaningfully extend how long the drug stays in your body. The CYP3A4 pathway is the more consequential one. In healthy volunteers, ketoconazole (a strong CYP3A4 inhibitor) increased oxycodone exposure two to threefold, along with increased drowsiness and nausea.16PubMed. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone Inhibiting CYP2D6 alone (tested with paroxetine, a common antidepressant) did not significantly change oxycodone’s overall exposure or side effects in that study.
The real problem arises when both pathways are blocked simultaneously. When volunteers took both paroxetine and itraconazole together, oxycodone exposure jumped nearly threefold.17PubMed Central. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone Common CYP3A4 inhibitors include certain antifungals, some antibiotics like clarithromycin, HIV protease inhibitors, and grapefruit juice in large quantities. CYP2D6 inhibitors include several antidepressants and some antihistamines. If you are taking any of these alongside oxycodone, the drug will linger in your system longer and hit harder, which matters both for drug testing and for safety.
Age and Body Weight
Oxycodone clearance declines with age. A population pharmacokinetic study found that the context-sensitive half-time increased from about 3.8 hours in a 25-year-old to about 4.6 hours in an 85-year-old, and steady-state concentrations were roughly 20 percent higher in elderly patients at the same dose.18British Journal of Anaesthesia. Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study That 20 percent increase may sound modest, but it compounds with the kidney and liver changes that often accompany aging, and it means an older adult may test positive noticeably longer than a younger person taking the same dose.
Body weight also plays a role. In surgical patients with obesity, total body weight was identified as a significant factor influencing both the clearance rate and the volume of distribution of intravenous oxycodone.19PubMed. Population Pharmacokinetics and Dosing Simulations of Intravenous Oxycodone for Perioperative Pain Relief in Adult Surgical Patients with Obesity Oxycodone is moderately lipophilic, so a larger body with more fatty tissue provides a bigger reservoir for the drug to distribute into. In practice, this can mean the drug trickles back out of fat stores over a longer period, potentially extending the tail end of detection in urine or blood.
Oxycodone in Breast Milk
For nursing mothers prescribed oxycodone after a cesarean section, the drug passes into breast milk at concentrations that can exceed those in the mother’s blood. A study of mothers receiving post-surgical oxycodone found a median milk-to-plasma ratio of about 3.2 to 1 during the first 24 hours. Over the following 48 hours, oxycodone persisted in the breast milk of some mothers even as their blood levels fell, with concentrations as high as 168 ng/mL detected. Oxycodone was found in the blood of one infant in the study.20PubMed. Oxycodone as a component of multimodal analgesia for lactating mothers after Caesarean section: relationships between maternal plasma, breast milk and neonatal plasma levels This means “how long does it stay in your system” extends, in a sense, to the breastfed infant, where immature liver enzymes make clearance even slower than in adults.
Urinary pH and Hydration
A large retrospective analysis of over 100,000 urine specimens from pain patients taking prescribed oxycodone examined how sex, age, urine pH, and concurrent medications influenced the concentrations and ratios of oxycodone and its metabolites in urine.21Journal of Analytical Toxicology. Observations of Urinary Oxycodone and Metabolite Distributions in Pain Patients Urinary pH matters because more acidic urine tends to trap oxycodone in its ionized form, keeping it in the urine rather than letting it be reabsorbed back into the bloodstream. In practical terms, someone who is dehydrated (producing concentrated, often more acidic urine) might show a higher concentration on a urine test, while someone who drinks large amounts of water might dilute their sample below a testing threshold even if the drug has not fully cleared. Laboratories account for dilution by checking urine creatinine levels, but the variability is real and can lead to confusing results for patients being monitored for prescription compliance.
This is one reason why a single urine test can produce a result that seems at odds with what you are actually taking. Pain management clinics that rely on urine drug monitoring often see unexpected negatives in patients who are genuinely taking their medication as prescribed, and unexpected positives in patients whose last dose was longer ago than standard detection windows would predict. The interplay between hydration, pH, metabolizer status, and which specific assay the lab uses makes any single detection window estimate just a rough average.
When Standard Timelines Do Not Apply
All of the detection windows described above assume a single dose in a person with normal organ function. Chronic use changes the picture. When you take OxyContin regularly over weeks or months, the drug and its metabolites accumulate in tissues and can take considerably longer to fully wash out. Someone who has been on a steady dose of OxyContin for months should expect detection times well beyond the two-to-three-day urine window that applies after one pill. There is no clean-cut number for this scenario because it depends on the dose, duration of use, and all the individual factors discussed throughout this article, but a week or more is plausible for urine detection after stopping chronic high-dose use.
Another situation where standard timelines fail is polysubstance use. If you are taking other medications that compete for the same liver enzymes, oxycodone’s metabolism slows down. Combining an SSRI antidepressant with an azole antifungal while also taking OxyContin, for instance, could substantially increase how long the opioid stays detectable, because both of the drug’s main metabolic exit routes are partially blocked at the same time.17PubMed Central. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone This is not a theoretical concern; it is one of the more common real-world causes of unexpectedly prolonged detection or unexpectedly strong side effects from a dose that previously felt routine.